Vasocure
524 Broadway
New York, NY 10013
www.vasocuretherapeutics.com

CONTACT INFORMATION
Eugene Dinescu, CEO
eugene@vasocuretherapeutics.com

INDUSTRY: Pharma

MANAGEMENT
Eugene Dinescu, BA Biochemistry, Columbia U., Columbia Executive Management Program, Former Director Flatlands Medical Associates, Founder, CEO
Anna Babinka, PhD Microbiology, Professor Department of Medicine SUNY Downstate, Founder, CSO
Elizabeth Kornecki, PhD Cell Biology, Former Professor Emeritus Department of Medicine, Founder, VP of R&D
Yigal Ehrlich, PhD Cell Biology, Former Professor Emeritus Department of Medicine CUNY, Founder, VP of R&D

BOARD
Moro Salifu, MD, MBA, MPH, Nephrologist, Chairman of SUNY Downstate Medical Center, Founder
Aditya Mattoo, MD, MBA, Former Professor of Medicine at NYU, Nephrologist, Founder

NUMBER OF EMPLOYEES: 10

FINANCE
Accountant: Manzi, Pino and Company PC
Funding to date:
Grants, $5M
Founders $500K

Financing sought: $5.5M
R&D $4.5M
Salaries and Legal $1M

INTELLECTUAL PROPERTY
Portfolio of Approved Patents: 3
Patent Applications filed: 4

Additional disclosed on slide deck

Legal
Abrams Law LLP

COMPANY BACKGROUND
Vasocure is a novel platform biotherapeutics company with over 62 drug candidates in nephrologyy, cardiology, and oncology. Vasocure was founded after 25 years of pioneering academic research including hundreds of publications and the discovery of the F11R Receptor, analogous to JAM-A. We are currently in the process of filing an IND for Pedifin, the world's first drug candidate shown to prevent and reverse neointimal disease in animal models.

UNMET NEED
- 15% of the US population (49 million people) is affected by chronic kidney disease (CKD) with a CAGR of 5.7%.
- 45% of CKD patients have diabetes or self-reported cardiovascular disease.
- 550,000 Americans suffer from kidney failure and are on hemodialysis through a vascular access.
- 100% of dialysis patients will require surgery

PRODUCTS/SERVICES – LAUNCHED & PIPELINE
- *Company owns and is developing 62 candidates including oral mimetics in nephrology, cardiology, and oncology.*
- *Focusing on neointimal disease (in the renal space due to FDA fast track (high priority indication)*

➢ Pedifin is a first-in-class, 1st generation, IV investigational drug that is a highly selective competitive inhibitor of F11R, currently seeking IND for FIH (First in human) Phase 1.
➢ F11R (F11 Receptor) is over-expressed in neointimal disease and atherosclerotic plaques.
➢ By blocking F11R, Pedifin can effectively inhibit narrowing of the lumen, which means better blood flows, better dialysis and better survival for patients.
➢ Pedifin, has been shown in animal models to be highly effective at preventing and reversing neointimal hyperplasia as well as atherosclerotic plaque formation.

MILESTONES
- Incorporated (Q4 2018)
- START-UP NY company, awarded 10 years tax-free operations (Q1 2019)
- Accepted in SUNY Downstate Incubator Labs (Q1 2020)
- State-of-the-art facilities in NYC and Lodz, Poland (Q1 2020)
- Successful completion of 95% preclinical studies with IND filing (Q4 2021)
- Estimated dose studies completed, 25mg/kg administered 1X/week
- Multiple IP filings (Q3-Q4 2021)

COMPETITION
- The only treatment is surgical, Pedifin is the first pharmacologic treatment.

FINANCIAL FORECAST
Forecast was derived using a Monte Carlo simulation based on preliminary calculations using two revenue components for the dialysis market: milestone payments and royalties from product sales.

	Year 1	Year 2	Year 3	Year 4	Year 5
Revenue ($000,000)	37	157	321	463	597
Growth rate (%)	-	424	204	144	128
Gross Profit ($000,000)	30	130	266	384	496
Gross Margin (%)	81	82	83	83	83